首页工具

ZSTK474

产品编号 T6168 CAS 475110-96-4

ZSTK474 是 ATP 竞争性的泛 I 类PI3K 抑制剂，抑制 PI3Kα、PI3Kβ、PI3Kδ 和 PI3Kγ，IC50分别为 16 nM、44 nM、4.6 nM 和 49 nM。它是一种可口服的 s-三嗪衍生物，具有抗肿瘤活性。

TargetMol的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。

ZSTK474, CAS 475110-96-4

规格	价格/CNY	货期
5 mg	￥ 246	现货
10 mg	￥ 426	现货
25 mg	￥ 795	现货
50 mg	￥ 1,390	现货
100 mg	￥ 2,570	现货
200 mg	￥ 3,890	现货
500 mg	￥ 6,250	现货
1 mL * 10 mM (in DMSO)	￥ 246	现货

大包装超大折扣，点击咨询

选择批次

纯度: 99.47%

纯度: 99.36%

纯度: 99%

纯度: 98.29%

更多批次查询请联系客服

生物活性

化学信息

存储 & 溶解度

参考文献

相关产品

产品描述	PI3K Inhibitor ZSTK474 is an orally available, s-triazine derivative, ATP-competitive phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity.
靶点活性	PI3Kδ:4.6 nM, PI3Kβ:44 nM, PI3Kα:16 nM, PI3Kγ:49 nM, PI3K:37 nM
体外活性	ZSTK474以1μM的浓度显著降低PI3K活性至对照水平的4.7%，而LY2194002只能将活性降低至44.6%。ZSTK474对重组的p110β、-γ和-δ的活性显示出强大的抑制作用，IC50分别为17 nM、53 nM和6 nM。相比LY294002和wortmannin（其平均GI50分别为7.4 μM和10 μM），ZSTK474对39种人类癌细胞系展现出更强的抗增殖活性，平均GI50为0.32 μM。在1μM的浓度下，ZSTK474能够阻断由血小板衍生生长因子在小鼠胚胎成纤维细胞（MEFs）中引起的膜皱褶形成和PIP3的产生。10 μM的ZSTK474诱导OVCAR3细胞凋亡，并在A549细胞中引发完全的G1期阻滞但不诱导凋亡。0.5μM浓度的ZSTK474显著降低磷酸化Akt和GSK-3β水平及cyclin D1蛋白表达，并以剂量依赖的方式抑制包括FKHRL1、FKHR、TSC-2、mTOR和p70S6K在内的其它下游信号组分的磷酸化，这些组分参与调控细胞增殖。[1]在0.1μM浓度下，ZSTK474不抑制mTOR，即使浓度达到100μM，ZSTK474对mTOR的活性抑制也不超过40%。[2]ZSTK474阻断VEGF诱导的人脐静脉内皮细胞（HUVECs）的细胞迁移和管状形成，并抑制RXF-631L细胞中HIF-1α的表达和VEGF的分泌，显示出强大的体外抗血管生成活性。[3]ZSTK474治疗抑制刀豆素A激活的T细胞中IFNγ和IL-17的产生，并抑制成纤维样滑膜细胞（FLS）的增殖和PGE(2)产生。[6]
体内活性	通过口服给药，ZSTK474以剂量依赖的方式抑制了小鼠皮下植入的B16F10黑色素瘤肿瘤的生长，在第14天时，分别以100, 200, 或400 mg/kg的剂量产生了28.5%, 7.1%, 或4.9%的肿瘤退缩率，优于四种主要抗癌化合物irinotecan, cisplatin, doxorubicin, 以及5-fluorouracil在其各自的最大耐受剂量下的肿瘤退缩率，分别为96%, 35.7%, 24%, 或68.3%。400 mg/kg的ZSTK474治疗完全抑制了小鼠体内A549, PC-3, 和WiDr异种移植瘤的生长，并引起A549异种移植瘤肿瘤的退缩。ZSTK474显著抑制了RXF-631L异种移植模型中的肿瘤生长，并与ZSTK474处理小鼠中显著减少的微血管数量相关。口服给药的ZSTK474改善了大鼠佐剂诱导的关节炎(AIA)的进展。
激酶实验	Inhibition of PI3K activity: A549 cells are lysed in a buffer containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, and 1% Igepal CA-630, the lysates are centrifuged at 20,000 g and 4 °C for 10 minutes, and the supernatants are used as cell lysate (protein = 2-4 mg/mL). To immunoprecipitate PI3K, 200 μL of cell lysate are incubated with anti-p85 polyclonal antibody and protein G-agarose (5 μL). PI3Kα, PI3Kβ, and PI3Kδ can be immunoprecipitated by the anti-p85 polyclonal antibody. Agarose beads containing immunoprecipitates are washed twice with buffer A (20 mM Tris-HCl at pH 7.5, 150 mM NaCl, 5 mM EDTA, and 1% Igepal CA-630), once with buffer B (500 mM LiCl and 100 mM Tris-HCl at pH 7.5), once with distilled water, and once with buffer C (100 mM NaCl and 20 mM Tris-HCl at pH 7.5). Immunoprecipitates are suspended in 20 μL of buffer C containing phosphatidylinositol of 200 μg/mL. The mixture is preincubated with increasing concentrations of ZSTK474 at 25 °C for 5 minutes. [γ-32P]ATP (2 μCi per assay mixture; final concentration, 20 μM) and MgCl2 (final concentration, 20 mM) are added to start the reaction. The reaction mixture is incubated at 25 °C for 20 minutes. Phosphorylated products of phosphatidylinositol are separated by thin-layer chromatography and visualized by autoradiography. The phosphatidylinositol-3-phosphate region is scraped from the plate, and radioactivity is also measured with liquid scintillation spectroscopy. The level of inhibition for ZSTK474 is determined as the percentage of 32P counts per minute obtained without ZSTK474.
细胞实验	Cells are exposed to increasing concentrations of ZSTK474 for 48 hours. The inhibition of cell proliferation is assessed by measuring changes in total cellular protein by use of a sulforhodamine B assay. Apoptosis is assessed by chromatin condensation or by flow cytometry. For chromatin condensation assay, cells are stained with Hoechst 33342 and examined by fluorescence microscopy. Morphologic changes induced by ZSTK474, such as the condensation of chromatin, are indicative of apoptosis. For flow cytometry analysis, cells are harvested, washed with ice-cold PBS, and fixed in 70% ethanol. Cells are then washed twice with ice-cold PBS again, treated with RNase A (500 μg/mL) at 37 °C for 1 hour, and stained with propidium iodide (25 μg/mL). The DNA content of the cells is analyzed with a flow cytometer. (Only for Reference)

分子量	417.41
分子式	C19H21F2N7O2
CAS No.	475110-96-4

存储

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度

DMSO: 8.75 mg/mL (20.96 mM), Sonication is recommended.

Ethanol: < 1 mg/mL (insoluble or slightly soluble)

H2O: < 1 mg/mL (insoluble or slightly soluble)

溶液配制表

可选溶剂	浓度体积质量	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3957 mL	11.9786 mL	23.9573 mL	59.8932 mL
	5 mM	0.4791 mL	2.3957 mL	4.7915 mL	11.9786 mL
	10 mM	0.2396 mL	1.1979 mL	2.3957 mL	5.9893 mL
	20 mM	0.1198 mL	0.5989 mL	1.1979 mL	2.9947 mL

计算器

摩尔浓度计算器

稀释计算器

配液计算器

分子量计算器

质量

浓度

容积

分子量

浓度 (起始)

容积 (起始)

浓度 (终)

容积 (终)

溶液体积

质量

配液浓度

参考文献

1. Yaguchi S, et al. J Natl Cancer Inst, 2006, 98(8), 545-556. 2. Kong D, et al. Cancer Sci, 2007, 98(10), 1638-1642. 3. Kong D, et al. Eur J Cancer, 2009, 45(5), 857-865. 4. Marone R, et al. Mol Cancer Res, 2009, 7(4), 601-613. 5. Yang S, et al. PLoS One, 2011, 6(10), e26343. 6. Wang P, et al. Class I PI3K inhibitor ZSTK474 mediates a shift in microglial/macrophage phenotype and inhibits inflammatory response in mice with cerebral ischemia/reperfusion injury. J Neuroinflammation. 2016 Aug 22;13(1):192. 7. Liu F, et al. Prolonged inhibition of class I PI3K promotes liver cancer stem cell expansion by augmenting SGK3/GSK-3β/β-catenin signalling. J Exp Clin Cancer Res. 2018 Jun 25;37(1):122. 8. Han H W, Hahn S, Jeong H Y, et al. LINCS L1000 dataset-based repositioning of CGP-60474 as a highly potent anti-endotoxemic agent[J]. Scientific reports. 2018 Oct 8;8(1):14969.

文献引用

1. Han H W, Hahn S, Jeong H Y, et al. LINCS L1000 dataset-based repositioning of CGP-60474 as a highly potent anti-endotoxemic agent. Scientific Reports. 2018 Oct 8;8(1):14969

剂量换算

对于不同动物的给药剂量换算，您也可以参考 更多...

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算，可以得到母液配置方法和体内配方的制备方法：比如您的给药剂量是10 mg/kg，每只动物体重20 g，给药体积100 μL，一共给药动物10 只，您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。

母液配置方法：2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL)，如您需要配置的浓度超过该产品的溶解度，请先与我们联系。

体内配方的制备方法：取 50 μL DMSO 主液，加入 300 μL PEG300，混匀澄清，再加 50 μL Tween 80，混匀澄清，再加 600 μL ddH2O, 混匀澄清。

第一步：请输入动物实验的基本信息

剂量

mg/kg

每只动物体重

给药体积

μL

动物数量

第二步：请输入动物体内配方组成，不同的产品配方组成不同，如有配方需求，可先联系我们提供正确的体内配方。

% DMSO+

% +